Agenus announces updated phase 1 data and progress on bot/bal development in metastatic mss colorectal cancer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its phase 1 clinical trial of bot/bal combination therapy in patients with metastatic crc that is not microsatellite instability-high (mss) or deficient mismatch repair (dmmr). these findings build upon the compelling clinical activity demonstrated by bot/bal across nine different cancer types in agenus' b.
AGEN Ratings Summary
AGEN Quant Ranking